Risk evaluation of carboplatin-induced allergy based on basophil activation test and FceRI expression.

2014 Fiscal Year Final Research Report

• Project/Area Number: 24590188
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: Mie University
• Principal Investigator: IWAMOTO Takuya 三重大学, 医学部附属病院, 准教授 (30447867)
• Co-Investigator(Kenkyū-buntansha): OKUDA Masahiro 三重大学, 医学部附属病院, 教授 (70252426)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 好塩基球 / バイオマーカー / カルボプラチン / 白金系抗がん薬 / アレルギー / IgE

Outline of Final Research Achievements

It is well known that platinum drugs induced severe hypersensitivity reaction (HR) after the repeated administration, and basophil activation was observed in patients with a history of carboplatin induced severe HR. However, the precise mechanism by which carboplatin induces basophil activation. To investigate whether IgE-dependent mechanisms, including the overexpression of FceRI, participate in carboplatin-induced basophil activation, 13 ovarian cancer patients were enrolled: 5 with a history of carboplatin-induced severe HR within the past 2 years, and 8 with no such history. Our results indicated that an IgE-dependent mechanism incorporating FceRI overexpression participates in carboplatin-induced severe HR.

Free Research Field

医療薬学